Interleukin-1-mediated inflammation is proposed to contribute to the development and progression of some cancers. IL-1 family member proteins are known to be expressed constitutively in many melanoma tumor cells, and we hypothesize that these support molecular pathways of inflammation and facilitate tumor growth. To investigate the expression of IL-1α and IL-1β in melanoma patients, and their association with disease progression, immunohistochemical staining was performed on tissues from 170 patients including benign nevi, primary melanomas, and metastatic melanomas. IL-1β levels were low (or zero) in benign nevi, and higher in primary and metastatic melanomas (P<0.0001). IL-1α was expressed in about 73% of nevi and 55% of metastatic melanomas, with levels significantly higher in primary tumors (P<0.0001); most (98%) primary melanoma samples were positive for IL-1α. In vitro studies with 7 human melanoma cell lines showed that 5 cell lines expressed IL-1α and IL-1β proteins and mRNA. We identified for the first time several important downstream signaling pathways affected by endogenous IL-1, including reactive oxygen and nitrogen species, COX-2, and phosphorylated IκB and SAPK/JNK; all of which were decreased by siRNA to IL-1s. Downregulation of IL-1α, IL-1β, or MyD88 substantially increased p21 and p53 levels. 
Introduction
Chronic inflammation not only facilitates the progression of normal cells to malignancy, but also supports survival of many malignancies through production of pro-inflammatory cytokines and reactive oxygen (ROS) and nitrogen species (RNS). Melanoma is one of these tumor types that is strongly associated with the inflammatory process, as melanoma are known to secrete high levels of cytokines and produce ROS and RNS (1) (2) (3) (4) . The cytokines expressed by melanoma cells function as paracrine regulators of the microenvironment, and possibly as tumor growth supporting factors. It has been shown that pro-inflammatory molecules, such as interferon-γ and IL-1, can activate and recruit myeloid-derived suppressor cells (MDSCs) to the tumor sites, resulting in strong suppression of various T-cell functions (5) (6) (7) (8) (9) . It is speculated that melanomaexpressed cytokines can stimulate MDSCs and promote highly immune-suppressed microenvironment. It is also well accepted that melanoma-expressed cytokines can also function as autocrine factors controlling tumor growth and metastasis. However, the scope and function of endogenous melanoma cytokines are poorly understood.
The constitutive expression of IL-1 has been shown to stimulate angiogenesis and promote tumor growth and metastasis in some human melanoma cells and mouse melanoma models (10) (11) (12) .
Thus, of all the melanoma-produced inflammatory factors, the interleukin-1 (IL-1) family of cytokines is of particular interest. The IL-1 family consists of two pro-inflammatory cytokines, IL-1α and IL-1β; an IL-1 receptor antagonist (IL-1Ra); and two different receptors, the biologically active IL-1 receptor type I (IL-1RI) and the inert IL-1RII (13) . One recent study reports that in the absence of exogenous stimuli, some human melanoma cells spontaneously produce functional IL-1β, which leads to constitutive activation of the inflammasome (14) . 4 Based on previous studies, we now hypothesize that the tumor-derived IL-1 promotes endogenous intracellular features of inflammation and thereby facilitates growth progression of human melanoma; also the downregulation of IL-1 signaling will suppress the growth of the IL-1-expressing melanoma.
Our group's initial study of six human melanoma cell lines and 29 melanoma tissues showed that tumor-secreted IL-1 can function in a paracrine fashion (15) . However, a more complete expression profile of IL-1α and IL-1β in melanoma has yet to be documented in vivo.
Furthermore, the mechanisms of melanoma-expressed IL-1 driving inflammation and tumor progression are not yet fully understood. In the immune system, it has been reported that binding of IL-1 to IL-1RI can lead to recruitment of the adaptor molecule MyD88, which subsequently activates several important kinase transduction cascades resulting in activation of NF-κB and other inflammatory genes such as cyclooxygenase-2 (COX-2) (16) (17) (18) . Whether autocrine IL-1 affects these inflammatory pathways in melanoma cells is still unclear.
In this study, we addressed the hypothesis presented above by testing the functional role of tumor-derived IL-1in melanoma growth in a series of in vitro experiments. Further, we tested the association of the protein levels of IL-1 with melanoma progression by examining a melanoma tissue microarray with cores from 170 patients utilizing immunohistochemical (IHC) techniques.
We identify for the first time several important downstream signaling pathways and markers that are affected by aberrant autocrine IL-1 in melanoma cells. We report here that blocking IL-1 signaling by specific siRNAs or IL-1RI-neutralizing antibody leads to the growth suppression in were from R&D Systems. Both nontarget and anti-human MyD88 SMARTpool siRNA were purchased from Dharmacon. Chimera RNAi for IL-1α and IL-1β were purchased from Novus Biologicals.
Melanoma tissue microarray.
The melanocytic tumor progression tissue microarray (TMA) was developed as a collaborative effort of the Harvard, M.D. Anderson, and University of Pennsylvania Skin SPOREs and served as a template for the investigation of IL-1 in human melanocytic tumors. This TMA was designed to provide samples of tumors from each step in melanocytic tumor progression (19) . The TMA contains 480 tissue cores from 170 patients, consisting of benign nevi (132 cores from 36 patients), primary cutaneous melanomas (196 cores 6 from 59 patients), melanoma metastases to lymph nodes (60 cores from 29 patients), and melanoma metastases to visceral organs (92 cores from 46 patients). Acral, mucosal, and uveal melanomas were excluded from this TMA (19) .
Immunohistochemical studies. We used an IHC protocol, described by us previously (20) , employing primary antibodies for IL-1α (1:100) and IL-1β (1:50). Immunolabeling was scored separately for two variables, first according to the percentage of melanoma cells with positive staining (<5% = 0, 5-25% = 1, 26-75% = 2, >75% = 3) and then according to the overall intensity of immunoreactivity of the positive cells (no staining = 0, light staining = 1, moderate staining = 2, marked staining = 3). Cases were considered to be positive if either the percentage or intensity scores were 1-3. The slides were manually scored independently by two researchers (SE and YQ) without prior knowledge of the tumor stage or data.
Cell culture and RNA isolation. Seven human melanoma cell lines were used in this study: A375, MeWo, SK-MEL-2, WM35, WM793, SB2, and TXM1, which were selected to represent the major somatically mutated and clinically relevant subtypes. Detailed information of each cell line and their authentication are provided in the Supplementary Data. Human melanoma cells were cultured in RPMI medium containing 100 U/mL penicillin, 100 μg/mL streptomycin, 200 mM L-glutamine, and 5% fetal bovine serum (FBS) (Sigma) at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . Human melanocytes were purchased from PromoCell (Heidelberg, Germany) and cultured in melanocyte growth medium 2 (PromoCell). Cells were maintained in logarithmic growth phase. Total cellular RNA was extracted using a NucleoSpin RNA II kit (Macherey-Nagel, Bethlehem, PA). Western blot analysis. Cells were lysed in buffer containing 50 mM Tris (pH 7.9), 150 mM NaCl, 1% NP-40, 1 mM EDTA, 10% glycerol, 1 mM sodium vanadate, and protease inhibitor cocktail (Roche). Proteins were separated by 8% SDS-PAGE gels, transferred to a Hybond ECL nitrocellulose membrane (GE Healthcare Biosciences, Piscataway, NJ), and blocked in 5% dry milk in PBS. The membrane was then incubated with primary and secondary antibodies, and target proteins were detected with ECL detection reagent (GE Healthcare Biosciences).
Reverse transcription PCR (RT-PCR).
To determine the mRNA levels of IL-1α and L-1β in melanoma cells, we performed first-strand cDNA synthesis with 400 ng of total RNA using a GeneAmp RNA PCR kit (Applied Biosystems, Carlsbad, CA) according to the manufacturer's protocol. A 2-μL cDNA product was used for each 25-μL PCR reaction t. The RT-PCR primers used to detect human IL-1α, IL-1β, and β-actin were adapted from those described previously (21, 22) . The PCR protocol consisted of initial denaturation at 95°C for 5 min; 30 cycles of 95°C 
Results
Expression profile of IL-1 in human melanoma tissues and cell lines. To determine whether melanoma cells express IL-1 in vivo, we used IHC to assess IL-1α and IL-1β protein levels on a TMA consisting of 480 tissue cores from clinically stratified melanoma specimens from 170 patients. We observed various positive-staining intensities and percentages in the cytoplasmic compartment of tumor cells for both IL-1α and IL-1β (Fig. 1A) . IL-1α and IL-1β protein expression characteristics varied with melanocytic tumor progression. We observed positive cytoplasmic staining (percentage score 1-3) for IL-1α protein in 73.2% of benign nevi, 98.4% of primary melanomas, and 55% of metastatic melanomas (Table 1A) . We observed the same trend for IL-1α staining intensity (Table 1A and 
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was significantly higher than nevus (P < 0.0001) and metastatic melanomas (P < 0.0001) (Fig.   1B , Table 1A ). Moreover, the IL-1α expression in thick primary melanomas was higher than thin primary melanomas, but there was no difference in IL-1α expression between lymph nodes and visceral metastasis melanomas. As shown in Table 1A , the positive cytoplasmic staining (percentage score 1-3) for IL-1β increased significantly from nevus (0%) to primary tumor (13.0 %) (P < 0.0001) and metastasis (9.8%) (P = 0.0001). Again, we observed the same trend for IL-1β staining intensity (Fig. 1C , Table 1A ). Due to the low number of positive samples, there was no significant difference of IL-1β levels between primary and metastatic melanomas.
The expression IL-1α was significantly higher than IL-1β in melanocytic tumor tissues for staining percentage and intensity (P < 0.0001) ( Table 1A ). The IL-1α and IL-1β double-positive samples only appeared in about 10% of primary and metastatic melanoma tissues but not in nevi (Table 1B) , where the IL-1β expression was rare. However, the tissue samples, which are double-positive to IL-1α and IL-1β increased significantly with progression from nevus to primary melanoma (P = 0.0001, both percentage and intensity scores) and from nevus to metastasis (P < 0.007, both percentage and intensity scores) (Table 1B) . Interestingly, all but one of the IL-1β-positive melanoma samples was also IL-1α-positive; the exception was one metastatic melanoma sample, suggesting that in melanoma cells, IL-1β expression strongly correlates with IL-1α expression. We also analyzed IL-1α and IL-1β protein levels based on the case number (patient number) of the TMA. The result of statistical analyses based on the case number showed the same trend of IL-1α and IL-1β expression profiles in nevi, primary melanoma, and metastatic melanoma as comparing with the result analyzed by core number (supplementary data).
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To explore the molecular mechanisms of autocrine IL-1 on melanoma cell growth in vitro, we examined the expression of IL-1α, IL-1β, and IL-1RI in human melanoma cell lines by western blot, RT-PCR, and IHC. Western blot analysis showed that all seven melanoma cell lines and the melanocytes expressed IL-1RI ( Fig. 2A) . A375, SB2, SK-MEL-2, WM35, and WM793 cells expressed high levels of IL-1α and IL-1β proteins, whereas the protein levels of IL-1α and IL-1β are extremely low in MeWo, TXM1, and the melanocytes ( The expression of IL-1α and IL-1β was confirmed to be negative in TXM1 cells and melanocytes ( was shown in supplementary data). Downregulation of IL-1α, IL-1β, MyD88, or both IL-1α and IL-1β inhibited IκB phosphorylation but did not affect the levels of total IκB in A375 and WM793 cells (Fig. 3C ) . Lipofectamine, alone or nontarget siRNA did not affect IκB phosphorylation. As IκB phosphorylation can release and activate the inflammatory factor NF-κB (23), our data suggest that constitutive endogenous IL-1 may constantly activate NF-κB in human melanoma cells by stimulating IκB phosphorylation. Furthermore, downregulation of MyD88 or IL-1α and IL-1β decreased COX-2 protein levels in A375 and WM793 cells compared with controls (Fig. 3C) . However, the IL-1α siRNA alone did not affect COX-2 levels.
The IL-1β siRNA could downregulate COX-2 levels in WM793 but not in A375 ( Figure 3C ).
These data suggest that elevated IL-1 signaling (both IL-1α and IL-1β) can promote COX-2 expression in melanoma cells.
The levels of NO and total ROS/RNS were measured in A375 and WM793 cells before and after downregulating MyD88 or IL-1α and IL-1β by siRNAs. Downregulating MyD88 or both IL-1α and IL-1β decreased red fluorescence intensity, indicating NO production, by 50-60% in A375 cells (P = 0.0009, Fig. 4A and B) . Similarly, downregulating MyD88 or both IL-1α and IL-1β decreased green fluorescence intensity, indicating a reduction of total ROS/RNS levels by 50-60% in A375 cells (P = 0.0007, Fig. 4A and C) . In contrast, nontarget siRNA did not affect the levels of NO or total ROS/RNS as compared to the lipofectamine control ( Fig. 4A-C) . These results indicate that autocrine IL-1 plays a critical role in sustaining oxidative stress in melanoma cells.
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Endogenous IL-1 regulates the levels of p21, p53, and phosphorylated SAPK/JNK in human melanoma cells. The tumor suppressors, p21 and p53, are sensors of diverse cellular stresses, including DNA damage and oxidative stress (24) . Thus, we examined whether the oxidative stress driven by aberrant endogenous IL-1 affected the levels of p21 and p53 in melanoma cells.
Downregulating IL-1α, IL-1β, or MyD88 increased p21 and p53 levels in A375 and WM793 cells compared with controls (Fig. 4D) , suggesting that aberrant autocrine IL-1 represses p21 and p53 expression in melanoma cells.
As kinase inhibitors have been successfully used in cancer therapy, we attempted to identify the major stress kinase regulated by endogenous IL-1 in melanoma cells. Downregulation of IL-1β or both IL-1α and IL-1β by siRNAs substantially decreased SAPK/JNK phosphorylation in A375 and WM793 cells but did not affect total SAPK/JNK levels (Fig. 4D) . However, the effect of downregulating only IL-1α or MyD88 on SAPK/JNK phosphorylation varied between A375 and WM793 cells. IL-1α downregulation inhibited SAPK/JNK phosphorylation in A375 cells but had only a slightly inhibitory effect on SAPK/JNK phosphorylation in WM793 cells. MyD88 downregulation produced similar results, which indicated that MyD88 may not be the major adaptor to mediate the major signaling pathway to activate SAPK/JNK by endogenous IL-1 in WM793 cells (Fig. 4D) . These data suggest that SAPK/JNK is one major signal transduction pathway that is regulated by autocrine IL-1 in melanoma cells. Furthermore, autocrine IL-1 may activate SAPK/JNK through signal transduction other than MyD88 in A375 and WM793 cells.
Our data suggests that activation of SAPK/JNK may be conducted through a MyD88-independent signaling pathway in WM793 cells. We also attempted to identify other kinases with goat IgG or no antibody, which was statistically significant (P = 0.04) (Fig. 5A) .
Furthermore, IL-1RI-neutralizing antibody did not significantly inhibit melanocytes growth (Fig.   5A ).
We also used a second method to assess the effect of endogenous IL-1 on growth of human melanoma cells. We applied the MTT cell proliferation assay in six melanoma cell lines after siRNA treatment for 72 h to block the IL-1 pathway. For the cell lines with high IL-1 expression-A375, WM793, WM35, and SB2-downregulating IL-1α, IL-1β, or MyD88 decreased cell proliferation by 30-65% (Fig. 5B) . In all four cell lines, downregulating both IL-1α and IL-1β decreased cell proliferation by 60-75% compared with nontarget siRNA treatment (Fig. 5B) . For the cell lines with low IL-1 expression, MeWo and TXM1, downregulating IL-1α, IL-1β, or MyD88 showed slightly 5-15% decreases of cell proliferation compared with the treatment of nontarget siRNA, which were not statistically significant. Thus, the blockage of IL-1 signaling did not inhibit cell proliferation significantly in MeWo and TXM1. These data suggest that autocrine IL-1 supports melanoma cell growth, and conversely that blocking the IL- (25, 26) . We found that in A375 cells, both the level of LC3-II and the ratio of LC3-II to LC3-I increased substantially after IL-1α, IL-1β, or MyD88 siRNA treatment (Fig. 6A) . In WM793 cells, IL-1α, IL-1β, and MyD88 siRNA treatment increased levels of both LC3-I and LC3-II (Fig. 6A) . Thus, blocking the IL-1 pathway triggered both the conversion of LC3-I to LC3-II and the synthesis of 
associated with autophagy (27) . As expected, downregulation of IL-1α, IL-1β, or MyD88 in A375 cells increased the percentage of cells with AVOs to 17.87%, 21.83%, and 13.31%, respectively, compared with nontarget siRNA and Lipofectamine controls (7.41% and 6.14%, respectively) (Fig. 6B) . Downregulation of both IL-1α and IL-1β increased the percentage of cells with AVOs to 29.89% (Fig. 6B) , approximately 4 times that of the controls in A375 cells. (Fig. 6D) . Collectively, our data show that blocking the IL-1 pathway can induce autophagy in melanoma cells with elevated IL-1 expression.
Discussion
We hypothesized that the tumor-derived IL-1 promotes endogenous inflammatory products that protein expression in a TMA with 480 tissue cores from 170 patients. By using this TMA, we were able to perform biostatistical analysis of IL-1α and IL-1β expression in melanocytic tumor progression for the first time. We found IL-1α and IL-1β were significantly elevated in primary melanoma, and that IL-1a was predominant. Such data also suggest that the elevated autocrine IL-1 signaling may be crucial for and primary melanoma development. Studies were then devised to interrupt the IL-1 signaling pathway, which resulted in decreasing reactive oxidative species and other proteins levels of COX-2, and phosphorylation of IκB and SAPK/JNK. Our studies indicate that the elevated oxidative stress induced by constitutive autocrine IL-1 is a driving force in chronic inflammation in human melanoma cells. The study from Dr. Fujita's group showed that melanoma cells spontaneously secreted IL-1β leading to constitutive activation of the NALP3 inflammasome, which contributed to the autoinflammation in human melanoma (14) . Along with the data from Dr. Fujita's group, our studies further confirm that the tumor-derived IL-1, including IL-1α and IL-1β, promotes inflammation and thereby facilitates growth progression of human melanoma. Our results also suggest that autocrine IL-1 suppresses p21 and p53 expression to low levels even under elevated oxidative stress. Furthermore, the interruption of endogenous IL-1 signaling could inhibit the growth of IL-1-expressing melanoma cells. Our results suggest that selectively inhibiting IL-1 signaling may be a promising therapeutic strategy in the subgroup of melanoma patients with constitutively high IL-1 expression.
In contrast to our finding, several studies showed that exogenous IL-1 could suppress the proliferation of some melanoma cells in vitro (28) (29) (30) (31) . These studies were mainly conducted in melanoma lines, A375.S2 and A375-6, which were sub-clones derived from A375 and have been Although IL-1β was expressed to a smaller extent (about 10%) in primary and metastatic melanoma than IL-1α, it is strongly correlated with IL-1α expression. Our studies indicated that downregulating both IL-1α and IL-1β inhibited melanoma cell growth more than blocking only IL-1α or IL-1β. We also found that IL-1α and IL-1β were expressed in both BRAF mutant (A375, WM35, and WM793) and BRAF wild-type (SK-MEL-2 and SB2) melanoma cells (supplementary data). Furthermore, the expression of IL-1α has been found in above 98% of primary melanoma from different genetic backgrounds. Thus, IL-1 is likely active in a large subpopulation of melanoma patients, and not related to BRAF mutations. We are now interested in conducting studies to determine why melanoma cells produce predominantly IL-1α rather than IL-1β;. as well as have initiated a study to investigate the expression profile of IL1Ra and its biological role in human melanoma cells. 
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For the first time, we report an association between the upregulation of IL-1 signaling and activated SAPK/JNK in human melanoma cells. Interestingly, MyD88 knockdown had a slight inhibitory effect on SAPK/JNK activation in WM793 cells, which is much weaker than the siRNA knockdown of IL-1α and IL-1β ( Figure 4D and supplementary data) . These results suggest heterogeneity of endogenous IL-1 downstream signaling in different melanoma cell lines.
We speculate that IL-1 may activate SAPK/JNK through the other Toll-like-receptor adaptors binding to IL-1RI, which are MyD88-independent. Previous studies have shown that TRIFrelated adaptor molecule (TRAM) was specifically involved in the Toll-like receptor-medicated MyD88-independent signaling pathway (32, 33) . Based on this unexpected data, we initiated a study to examine the role of TRAM on activating SAPK/JNK by IL-1 in WM793 cells. In our preliminary study, the knockdown of TRAM by specific siRNA did not show any significant 
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The expression of IL-1α and IL-1β is significantly elevated in primary melanoma indicating that the elevated endogenous IL-1 and related downstream signaling may be crucial for primary melanoma development. Recent studies from Dr. Lynda Chin's group showed that the mutated BRAF alone was not sufficient to transform melanocytes in vivo (35) . However, the UVinduced robust activation of JNK might be considered as part of the additional factor(s) needed to transform BRAF-mutated melanocytes (35) . The observation of IL-1 elevation in primary melanoma suggests that the autocrine IL-1-induced activation of JNK may play a critical role in melanocytes transformation and tumor initiation in the absent of risk factors, such as UV radiation. We are currently investigating the role of JNK in mediating oncogenic behavior driven by aberrant endogenous IL-1 in melanoma and the potential of using JNK inhibitors to inhibit melanoma cell growth.
To our knowledge, this is the first study to show that the IL-1 signaling pathway regulates autophagy in human melanoma cells. Recent studies showed that SAPK/JNK activation occurred downstream of autophagy induction and was dependent on the autophagic process in mice (36, 37) . Our results suggest that IL-1 may be a key link between SAPK/JNK and autophagy, however, further investigation is needed to determine whether the linkage between IL-1 signaling, SAPK/JNK, and autophagy exists in human melanoma cells.
In clinical studies, the accumulation of MDSCs has been shown to functionally suppress the immune response in melanoma patients (38). It is known that IL-1 can stimulate MDSCs (7). Therefore, we speculate that the constitutive melanoma-expressed IL-1 can activate and recruit MDSCs to tumor sites resulting in immunosuppression. This mechanism may, in part, explain The important mutations of these cell lines were summarized in Table S1 . The siRNA knockdown of TRAM in WM793 cells. The anti-human TRAM SMARTpool siRNA was purchased from Dharmacon. The RT-PCR primers used to detect human TRAM mRNA were 5'-GGGAGCTCAGAGCGTGGAA-3' and 5'-GGCAATAAATTGTCTTTGTACCAT-3', which were designed based on the NCBI Reference Sequence, NM_021649.6.
Results

Specifically downregulating IL-1β expression in WM793 cells with anti-IL-1β siRNA.
WM793 cells were transfected by specific siRNA against IL-1α, IL-1β, MyD88, respectively.
The effectiveness and specificity of anti-IL-1β siRNA on the expression of IL-1β in WM793 cells were demonstrated by western blot after 24-hour siRNA transfection (Fig. S1 ).
Statistical analyses of IL-1α and IL-1β expression profiles in nevi, primary melanoma, and metastatic melanoma according to case number (patient number). We used IHC to assess IL-1α and IL-1β protein levels on a TMA consisting of 480 tissue cores from clinically stratified melanoma specimens from 170 patients. We analyzed IL-1α and IL-1β protein levels based on the case number (patient number) of the TMA. The statistical analyses results showed the same trend of IL-1α and IL-1β expression profiles in nevi, primary melanoma, and metastatic melanoma as compared with the result analyzed by tissue core number. We observed positive staining for IL-1α protein in 62.9% of patients' benign nevi, 96.5% of patients' primary melanomas, and 55.3% of patients' metastatic melanomas (Table S1 ). We observed the same trend for IL-1α staining intensity (Table S1 and Fig. S2A ). IL-1α expression in primary melanomas was significantly higher than nevus (P < 0.0001) and metastatic melanomas (P < Fig. S4B ). This result indicates that TRAM signaling may not be the major pathway to activate SAPK/JNK in WM793 cells. 
